INNO Share Price | InnoCan Pharma Corp. Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Compare InnoCan Pharma Corp. with Similar Stocks

BioSyent, Inc.Defence Therapeutics Inc NervGen Pharma Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

The company has declared Positive results for the last 13 consecutive quarters

OPERATING CASH FLOW(Y) Highest at CAD -2.16 MM
NET SALES(HY) At CAD 19.32 MM has Grown at 59.1%
ROCE(HY) Highest at -38.58%

Risky - Negative EBITDA

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 30 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.04

Return on Equity

-29.64%

Price to Book

3.86

Revenue and Profits:

Net Sales:

7 Million

(Quarterly Results - Dec 2025)

Net Profit:

3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-15.66%

6 Months

-68.65%

1 Year

-54.44%

2 Years

-70.71%

3 Years

-64.35%

4 Years

-85.09%

5 Years

-85.09%

InnoCan Pharma Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

107.90%

EBIT Growth (5y)

11.29%

EBIT to Interest (avg)

-3.31

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.09

Sales to Capital Employed (avg)

4.57

Tax Ratio

56.25%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.24

EV to EBIT

-11.66

EV to EBITDA

-12.02

EV to Capital Employed

-7.31

EV to Sales

0.53

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-46.41%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -25.53% vs -3.09% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 213.04% vs -475.00% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.00",
          "val2": "9.40",
          "chgp": "-25.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.30",
          "val2": "-1.70",
          "chgp": "23.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "3.50",
          "val2": "-0.50",
          "chgp": "800.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2.60",
          "val2": "-2.30",
          "chgp": "213.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-184.80%",
          "val2": "-178.50%",
          "chgp": "-0.63%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -7.69% vs 119.02% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -25.00% vs 92.98% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "37.20",
          "val2": "40.30",
          "chgp": "-7.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.70",
          "val2": "-1.70",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.80",
          "val2": "3.00",
          "chgp": "-40.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.50",
          "val2": "-0.40",
          "chgp": "-25.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-47.20%",
          "val2": "-42.40%",
          "chgp": "-0.48%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

7.00

9.40

-25.53%

Operating Profit (PBDIT) excl Other Income

-1.30

-1.70

23.53%

Interest

0.00

Exceptional Items

3.50

-0.50

800.00%

Consolidate Net Profit

2.60

-2.30

213.04%

Operating Profit Margin (Excl OI)

-184.80%

-178.50%

-0.63%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is -25.53% vs -3.09% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 213.04% vs -475.00% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

37.20

40.30

-7.69%

Operating Profit (PBDIT) excl Other Income

-1.70

Interest

0.00

Exceptional Items

1.80

3.00

-40.00%

Consolidate Net Profit

-0.50

-0.40

-25.00%

Operating Profit Margin (Excl OI)

-47.20%

-42.40%

-0.48%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -7.69% vs 119.02% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -25.00% vs 92.98% in Dec 2024

All Annual Results

Company CV

About InnoCan Pharma Corp.

InnoCan Pharma Corp.

Pharmaceuticals & Biotechnology

Innocan Pharma Corporation is an Israel-based pharmaceutical company active in the medical cannabis industry. It operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The Company is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.

Company Coordinates

Company Details

10 Hamenofim Street , HERZLIYA None : 4672561

Tel:

https://innocanpharma.com/

Registrar Details